ADA Scientific Sessions 2025 Abstract

Glucometabolic Outcomes in Patients with Concurrent Overweight/Obesity and Type 1 Diabetes following Prolonged Glucagon-Like Peptide 1 Receptor Agonist Treatment—A Systematic Review and Meta-analysis

By Amanda R. Purcell, Xi May Zhen, Sarah SG Glastras

ReviewInterventions

The paper

Amanda R. Purcell, Xi May Zhen, Sarah SG Glastras

Camperdown

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, late-breaking 1977-LB

doi.org/10.2337/db25-1977-lb

The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial